- Home
- RVMD vs MKL Comparison
RVMD vs MKL Comparison
Compare RVMD & MKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVMD | MKL |
|---|---|---|
| Founded | 2014 | 1930 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 24.8B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | RVMD | MKL |
|---|---|---|
| Price | $189.23 | $1,888.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 1 |
| Target Price | $140.84 | ★ $2,100.00 |
| AVG Volume (30 Days) | ★ 1.8M | 59.7K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 73.57 |
| Revenue | N/A | ★ $15,513,233,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $533.02 | $2.26 |
| P/E Ratio | ★ N/A | $25.55 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.00 | $1,719.41 |
| 52 Week High | $194.56 | $2,207.59 |
Technical Indicators
Market Signals| Indicator | RVMD | MKL |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 41.71 |
| Support Level | $176.00 | $1,863.07 |
| Resistance Level | $193.83 | $2,013.77 |
| Average True Range (ATR) | 7.45 | 39.66 |
| MACD | -0.96 | -10.49 |
| Stochastic Oscillator | 58.24 | 13.15 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About MKL Markel Group Inc.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The acquisition of Alterra in 2013 added substantial reinsurance operations, which now account for a little over 10% of premiums. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.